Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$27.35
$0.49(1.79%)
At close: 4:00 PM EDT
$27.35
$0.49(1.79%)
Day’s Range― - ―
52-Week Range$15.10 - $31.77
Previous Close$28.11
Volume1.20M
Average Volume (3M)1.61M
Market Cap
$3.15B
Enterprise Value$3.44K
Total Cash (Recent Filing)$238.55M
Total Debt (Recent Filing)$114.14M
Price to Earnings (P/E)113.6
Beta0.75
Next Earnings
Oct 29, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding125,691,960
10 Day Avg. Volume1,201,154
30 Day Avg. Volume1,611,591
Financial Highlights & Ratios
PEG Ratio2.52
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.57Price Target Upside33.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.22
Revenue Forecast (FY)$500.06M
Bulls Say, Bears Say
Bulls Say
ZORYVE Commercial MomentumStrong prescription growth and rising product revenue indicate expanding adoption of ZORYVE across dermatology indications. Sustained demand can support a broader commercial base and improve operating leverage as the franchise scales.
Profitability And Cash-flow InflectionThe return to quarterly profitability and positive operating cash flow strengthens financial self-funding capacity. Continued cash generation could reduce reliance on external capital while supporting commercial investment and pipeline development.
Franchise Expansion And IP ProtectionPediatric approval expands the addressable patient population, while additional patents and long exclusivity timelines support franchise durability. Broader indications and stronger protection can reinforce ZORYVE's market position over multiple years.
Bears Say
Gross-to-net PressurePersistently high gross-to-net deductions reduce the revenue retained from prescription volume and constrain margin expansion. Limited near-term improvement means stronger demand may not translate proportionally into durable net sales or profitability.
Elevated Commercial InvestmentHigher sales and marketing costs can suppress operating leverage while Arcutis expands its commercial organization and access initiatives. The investment may pay off, but durable margin improvement depends on revenue growth outpacing the enlarged cost base.
Pipeline And Commercial Execution RiskPipeline programs remain exposed to proof-of-concept and timing risk, limiting visibility beyond ZORYVE. At the same time, a commercial leadership transition adds execution uncertainty while the company is scaling sales and expanding indications.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?
Arcutis Biotherapeutics Inc lowest stock price was $15.10 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics Inc’s market cap?
Arcutis Biotherapeutics Inc’s market cap is $3.15B.
When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?
Arcutis Biotherapeutics Inc’s upcoming earnings report date is Oct 29, 2026 which is in 67 days.
How were Arcutis Biotherapeutics Inc’s earnings last quarter?
Arcutis Biotherapeutics Inc released its earnings results on Aug 05, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.055 by $0.055.
Is Arcutis Biotherapeutics Inc overvalued?
According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued.
Does Arcutis Biotherapeutics Inc pay dividends?
Arcutis Biotherapeutics Inc does not currently pay dividends.
What is Arcutis Biotherapeutics Inc’s EPS estimate?
Arcutis Biotherapeutics Inc’s EPS estimate is 0.18.
How many shares outstanding does Arcutis Biotherapeutics Inc have?
Arcutis Biotherapeutics Inc has 125,691,960 shares outstanding.
What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?
Arcutis Biotherapeutics Inc reported an EPS of $0.11 in its last earnings report, beating expectations of $0.055. Following the earnings report the stock price went down -2.472%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.57 (33.72% Upside)
$36.57 (33.72% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $465.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.62%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated robust commercial momentum and multiple strategic wins — sizable revenue growth (+59% YoY), a return to quarterly profitability, raised full-year guidance, recent pediatric approval and an accepted sNDA — while simultaneously investing heavily in commercial expansion, patient access initiatives, and a broad pipeline. Near-term challenges include elevated SG&A from the salesforce build, gross-to-net still in the 50s with only moderate near-term improvement, early-stage readout risk on several programs, and some uncertainty around telehealth conversion dynamics. On balance, positive operational and financial momentum outweigh the manageable risks.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$36.57
▲(33.72% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.51% Insiders
16.01% Mutual Funds
48.32% Other Institutional Investors
12.71% Public Companies and
Individual Investors